Rob Dillard

DocwireNews

A study found a sharp decline in in cancer and precancer diagnoses during the first surge of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/covid-19-update-president-elect-biden-outlines-1-9-trillion-coronavirus-relief-plan-fauci-says-100-million-doses-in-bidens-first-100-days-is-doable-and-more/">COVID-19</a> due to a reduction in cancer screening tests performed.&nbsp; The study appeared in JAMA Oncology.&ldquo;It&rsquo;s widely thought that fewer people were screened for cancer and precancerous lesions during the first surge of the pandemic, because of limitations on non-urgent medical procedures, restrictions on patient volume, and patients&rsquo; concerns about the spread of the virus and the need for social distancing,&rdquo; says Ziad Bakouny, MD, MSc, of Dana-Farber Cancer Institute, a co-first author of the study via a <a href="https://www.eurekalert.org/pub_releases/2021-01/dci-sss011321.php">press release</a>. &ldquo;For this study, we wanted to document the extent of this decline, and its impact on cancer diagnoses, at a major U.S. health care system.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Study shows sharp decline in <a href="https://twitter.com/hashtag/Cancer?src=hash&amp;ref_src=twsrc%5Etfw">#Cancer</a> screenings, diagnoses during the first COVID-19 surge <a href="https://t.co/EOganbD9KV">https://t.co/EOganbD9KV</a><a href="https://twitter.com/hashtag/HealthCareSystemsServices?src=hash&amp;ref_src=twsrc%5Etfw">#HealthCareSystemsServices</a> <a href="https://twitter.com/hashtag/MedicineHealth?src=hash&amp;ref_src=twsrc%5Etfw">#MedicineHealth</a> <a href="https://twitter.com/hashtag/PublicHealth?src=hash&amp;ref_src=twsrc%5Etfw">#PublicHealth</a> <a href="https://twitter.com/hashtag/science?src=hash&amp;ref_src=twsrc%5Etfw">#science</a> <a href="https://t.co/4vyDA37og6">pic.twitter.com/4vyDA37og6</a>
&mdash; Bioengineer.org (@bioengineerorg) <a href="https://twitter.com/bioengineerorg/status/1349762302090817536?ref_src=twsrc%5Etfw">January 14, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;In this study, researchers assessed cancer screenings and diagnoses over four 3-month periods. The first, during the initial peak of the pandemic in the New England area from March 2 to June 2, 2020. This period was compared with three control periods before and after the main study period, the researchers noted. Subsequently, they compared the decrease in screening tests and in diagnoses during the pandemic period and computed each of the control periods as percentage decrease.According to the results, there was a sharp decline in cancer screening during the peak period of COVID-19. Overall, researchers observed that a total of 15,453 patients underwent screening exams in the March-June time frame, juxtaposed to 64,269 in the previous three months and 60,344 in the same three months of 2019. Optimistically, the researchers showed that screenings recovered to almost pre-pandemic levels in the three-month post-peak period, to 51,944.&ldquo;This investigation is especially timely given that we are currently dealing with a second, and potentially worse wave of the pandemic,&rdquo; says co-senior author Quoc-Dien Trinh, MD, of Brigham and Women&rsquo;s Hospital (BWH). &ldquo;We have learned to leverage a redesigned patient flow, increased use of telehealth, and made other accommodations to allow our patients to continue receiving standard of care cancer screening and diagnosis in the safest possible environment.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Study shows sharp decline in cancer screenings, diagnoses during the first COVID-19 surge<a href="https://twitter.com/hashtag/Oncology?src=hash&amp;ref_src=twsrc%5Etfw">#Oncology</a> <a href="https://twitter.com/hashtag/MedTwitter?src=hash&amp;ref_src=twsrc%5Etfw">#MedTwitter</a> <a href="https://twitter.com/hashtag/MedEd?src=hash&amp;ref_src=twsrc%5Etfw">#MedEd</a><a href="https://t.co/IqQCdbWIii">https://t.co/IqQCdbWIii</a>
&mdash; MedPub Oncology (@MedPubOnco) <a href="https://twitter.com/MedPubOnco/status/1349866314328805377?ref_src=twsrc%5Etfw">January 14, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Oncology News Update: 'Study shows sharp decline in cancer screenings, diagnoses during the first COVID-19 surge' has been published on Oncology News Australia &ndash; <a href="https://t.co/52edM8mfRQ">https://t.co/52edM8mfRQ</a> <a href="https://twitter.com/hashtag/oncnews?src=hash&amp;ref_src=twsrc%5Etfw">#oncnews</a> <a href="https://t.co/Bgmc0g7ksX">pic.twitter.com/Bgmc0g7ksX</a>
&mdash; Oncology News Australia (@OncologyNewsAus) <a href="https://twitter.com/OncologyNewsAus/status/1351173596308234244?ref_src=twsrc%5Etfw">January 18, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;&nbsp;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Study Shows Considerable Decline in Cancer Screenings, Diagnoses During First Wave of COVID-19

COVID-19

A study found a sharp decline in in cancer and precancer diagnoses during the first surge of COVID-19 due to a reduction in cancer screening tests performed.  The study ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe